EN DE
Watch Yatharth Hospital & Trauma Care Services Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Yatharth Hospital & Trauma Care Services Limited (YATHARTH) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Yatharth Hospital & Trauma Care Services Limited stock ₹340, price ₹1,069, that is 68.2% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE0JO301016

YH Yatharth Hospital & Trauma Care Services Limited logo Some data Nov 11, 2026

Yatharth Hospital & Trauma Care Services Limited

YATHARTH · NSE

Far too expensive (fair value 68% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Solidly profitable · 13.2% net margin (TTM) 
Low debt 
Revenue last quarter +52% vs. a year ago. 
Expensive Growth (revenue 5y +39.5 %/yr in INR) 
Mixed vs. peers (6/13) 
Moderate moat 54/100 · thin data
Some data 
Fair value ₹340.37 · Strongly overvalued 
Quality 39/100 
Negative free cash flow 
⚠ Dilution
Watch Yatharth Hospital & Trauma Care Services Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,162 ₹312.25 Fair Value ₹340.37 Aug 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

39‑month range ₹312.25 – ₹1,162 · fair‑value band ₹255.28 – ₹425.46 · the ₹1,069 price screens above the ₹340.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Yatharth Hospital & Trauma Care Services in your weekly email

Every Wednesday you see whether Yatharth Hospital & Trauma Care Services is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India.

Show moreShow less

The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant.

It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery.

In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.

Stock analysis

Yatharth Hospital & Trauma Care Services Limited (YATHARTH) currently trades at ₹1,069, while our model-based Fair Value estimate is ₹340.37, 68% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹845.64 per share, and 0 of the 14 models we run sit above the ₹1,069 price.

Bear case: the Economic Profit group reads lowest at ₹131.63, and 14 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ₹255.28 (bear) to ₹425.46 (bull), the price of ₹1,069 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Yatharth Hospital & Trauma Care Services Limited reported revenue of ₹12.1B in FY2026 versus ₹4.0B in FY2022, a compound +31.7%/yr. Reported net income was ₹1.8B in FY2026, compounding +41.2%/yr from FY2022.

Key figures

Market cap ₹103B (≈ $1.1B) Small · P/E ratio 56.9 · P/S ratio 7.54 · EPS (TTM) ₹18.80 · Net margin 13.2% · Return on equity 9.9% · Return on assets (EBIT) 15.1% (5-year average) · Operating margin 16.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 94% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −68%, YATHARTH screens richer than that median.

Fair Value models

Bear ₹255.28 Fair Value ₹340.37 Bull ₹425.46
Price ₹1,069 · Downside -68.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹11.85 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV ₹105.96 ₹117.03 ₹125.85 74
ROIC Compounder ₹105.96 ₹117.03 ₹125.85 70
Residual Income ₹139.57 ₹146.22 ₹162.55 68
All 14 models by family
Earnings-Based
Graham-Dodd ₹123.77 ₹863.16 ₹1,211 61
Lynch FV ₹445.94 ₹637.05 ₹828.17 59
PEG = 1.0 ₹445.94 ₹637.05 ₹828.17 55
EPV ₹105.96 ₹117.03 ₹125.85 74
Multiples
P/E Multiple ₹300.33 ₹400.43 ₹500.54 63
P/S Multiple ₹232.07 ₹309.43 ₹386.78 58
P/B Multiple ₹516.37 ₹688.49 ₹860.61 55
EV/EBIT ₹270.27 ₹360.39 ₹450.51 66
EV/EBITDA ₹318.25 ₹424.36 ₹530.47 67
EV/Revenue ₹192.88 ₹275.57 ₹358.27 53
Asset-Based
NCAV (Graham) ₹14.46 ₹21.90 ₹27.38 54
Economic Profit
Residual Income ₹139.57 ₹146.22 ₹162.55 68
ROIC Compounder ₹105.96 ₹117.03 ₹125.85 70
Growth Earnings
Growth-Adj P/E ₹591.95 ₹845.64 ₹1,099 65

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 47
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 86
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 56
How calm the share price moves, does not count
Price momentum 78
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 83
Distance to the 52-week high, does not count
New shares 21
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+37.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.5%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+38.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+38.1%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 17%

YATHARTH screens overvalued: fair value 68% below the price. Compare with HCA Healthcare, Inc →

Compare Yatharth Hospital & Trauma Care Services Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −68.2% · Bottom 25%
Profitability
Return on equity (12 months) 9.9% · Above median
Return on assets 7.7% · Above median
Net margin (12 months) 13.2% · Top 25%
Operating margin (12 months) 16.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 52.3% · Top 25%
Dividend yield (12 months) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.13× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 56.9× · Priciest 25%
P/B 5.79× · Priciest 25%
P/S (12 months) 7.54× · Priciest 25%
EV/EBITDA 30.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)100 · sector 33
PAST (return on equity)40 · sector 32
HEALTH (low debt)94 · sector 90
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Yatharth Hospital & Trauma Care Services Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Yatharth Hospital & Trauma Care Services Limited Fair Value". https://www.fairvalue-calculator.com/stock/YATHARTH

Frequently asked questions

Is Yatharth Hospital & Trauma Care Services Limited (YATHARTH) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹340.37 versus a price of ₹1,069, about 68% lower (overvalued).
What is the fair value of YATHARTH?
Our model-based fair value for Yatharth Hospital & Trauma Care Services Limited is ₹340.37 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹1,069.
What is the quality score of YATHARTH?
Yatharth Hospital & Trauma Care Services Limited has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Our model-based price target is the fair value of ₹340.37 (as of Nov 11, 2026) from 14 valuation models. Cautious scenario ₹255.28, optimistic scenario ₹425.46. It is a calculation from audited fundamentals, not an analyst target.
What is the Yatharth Hospital & Trauma Care Services Limited stock forecast for 2026?
Our models put fair value at ₹340.37, about 68% lower versus a price of ₹1,069 (overvalued). Cautious scenario ₹255.28, optimistic scenario ₹425.46. The calculation is refreshed regularly with new filings.
What is the revenue of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Yatharth Hospital & Trauma Care Services Limited reported trailing-twelve-month revenue of about ₹13.7B (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yatharth Hospital & Trauma Care Services Limited it is ₹340.37 per share (as of Nov 11, 2026), against a price of ₹1,069. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Yatharth Hospital & Trauma Care Services Limited stock overvalued or undervalued in 2026?
As of Nov 11, 2026, YATHARTH trades above its calculated fair value: price ₹1,069, fair value ₹340.37, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of YATHARTH?
No. The price is what the market pays today (₹1,069); the fair value is what the company's own numbers justify (₹340.37). For Yatharth Hospital & Trauma Care Services Limited the two are ₹728.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Yatharth Hospital & Trauma Care Services Limited worth?
The market values Yatharth Hospital & Trauma Care Services Limited at about ₹103B (market capitalisation, as of Nov 11, 2026). Per share that is ₹1,069; our models calculate a fair value of ₹340.37 per share.
What do the bullish and bearish scenarios say about YATHARTH?
Our models span a range for Yatharth Hospital & Trauma Care Services Limited: cautious scenario ₹255.28, base ₹340.37, optimistic ₹425.46 per share (as of Nov 11, 2026, price ₹1,069). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of YATHARTH?
Yatharth Hospital & Trauma Care Services Limited trades at a price-to-earnings ratio of 56.9 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹340.37 is built from several models across several years. Other multiples: P/B 5.8, P/S 7.5, EV/EBITDA 30.3.
How solid is the balance sheet of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Balance-sheet figures for Yatharth Hospital & Trauma Care Services Limited (as of Nov 11, 2026): return on equity 9.9%, debt of 0.13 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is YATHARTH from its 52-week high?
Yatharth Hospital & Trauma Care Services Limited trades at ₹1,069, about 8% below its 52-week high of ₹1,162 and 94% above the low of ₹550.80 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹340.37 is for.
Which stocks are comparable to Yatharth Hospital & Trauma Care Services Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yatharth Hospital & Trauma Care Services Limited stock attractive at the current price?
The data as of Nov 11, 2026: price ₹1,069, calculated fair value ₹340.37 (−68%), Quality Score 39/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of YATHARTH calculated?
We run Yatharth Hospital & Trauma Care Services Limited through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹340.37 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Yatharth Hospital & Trauma Care Services Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The closing price on Nov 16, 2026 was ₹1,069. Our model-based fair value is ₹340.37, about 68% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yatharth Hospital & Trauma Care Services Limited right now?
The price sits above even our optimistic bull case (₹425.46). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Yatharth Hospital & Trauma Care Services Limited

How large is the market capitalisation of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The market capitalisation of Yatharth Hospital & Trauma Care Services Limited is ₹103B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The price-to-sales ratio of Yatharth Hospital & Trauma Care Services Limited is 7.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Earnings per share at Yatharth Hospital & Trauma Care Services Limited are ₹18.80 (price ÷ EPS = P/E 56.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The net margin of Yatharth Hospital & Trauma Care Services Limited is 13.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The return on equity (ROE) of Yatharth Hospital & Trauma Care Services Limited is 9.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
On an EBIT basis the return on assets of Yatharth Hospital & Trauma Care Services Limited is 15.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The operating margin of Yatharth Hospital & Trauma Care Services Limited is 16.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Revenue at Yatharth Hospital & Trauma Care Services Limited is growing 52.3% versus a year earlier (3y avg +32.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Earnings per share at Yatharth Hospital & Trauma Care Services Limited are growing 11.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yatharth Hospital & Trauma Care Services Limited (YATHARTH) generate?
The free cash flow of Yatharth Hospital & Trauma Care Services Limited is −₹957M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Yatharth Hospital & Trauma Care Services Limited (YATHARTH) carry?
The net debt of Yatharth Hospital & Trauma Care Services Limited is ₹7.3M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Yatharth Hospital & Trauma Care Services Limited in the live analysis

One click puts Yatharth Hospital & Trauma Care Services Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.